Today: 7 February 2026
Subscribe
Browse Category

Mergers & Acquisitions News 10 October 2025 - 15 October 2025

Shocking Surge: Hillenbrand Stock Soars 19% on $32 Buyout Announcement

Shocking Surge: Hillenbrand Stock Soars 19% on $32 Buyout Announcement

Lone Star Buyout Details Hillenbrand (NYSE: HI) announced on Oct. 15 that it will be acquired by Lone Star Funds in an all-cash deal at $32.00 per shareir.hillenbrand.com. At this price, the transaction’s enterprise value is roughly $3.8 billion, including Hillenbrand’s debt. The board said it reviewed multiple strategic options and unanimously determined the offer “is in the best interest of Hillenbrand and its shareholders”ir.hillenbrand.com. Lone Star’s offer represents a 37% premium to Hillenbrand’s pre-deal share price on Aug. 12ir.hillenbrand.com, and 53% above the 90-day average price up to that date. The companies expect the deal to close by the end of
15 October 2025
····
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseasesinvestor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rightsinvestor.omeros.comreuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the newsreuters.com, and by market close had settled near $10.10investing.com. TechStock² (ts2.tech) notes Omeros shares surged roughly 65% on the announcementts2.tech. The deal is structured as an asset purchase and license – not
15 October 2025
······
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties Novonordisk. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug Reuters. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 Marketscreener Novonordisk. Novo’s Chief Scientific
15 October 2025
······
Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

HOND stock has surged into the mid-$20s (around $24.98 as of Oct. 15, 2025) after trading in the high teens last week Investing Marketbeat. Its volume spiked (about 1.14 million shares on Oct. 13) and the stock gapped up from $18.86 to $21.69 at open on Oct. 13 Marketbeat. – The catalyst is a proposed merger with Terrestrial Energy Inc., a next-gen nuclear reactor company. The SEC declared the merger’s S-4 registration effective on Sept. 26, and HCM II shareholders will vote on Oct. 20 to approve the deal Businesswire Businesswire. If approved, the combined firm will list on Nasdaq
15 October 2025
····
Urban-gro Stock Skyrockets on Flashy Merger Deal – Is This the Cannabis Builder’s Comeback?

Urban-gro Stock Skyrockets on Flashy Merger Deal – Is This the Cannabis Builder’s Comeback?

Merger with Flash Sports & Media Sparks Stock Surge Urban-gro’s announcement of a planned merger with Flash Sports & Media sent its battered stock soaring on October 14. The company revealed it signed a binding LOI to combine with Flash, a private sports-media firm, in what is effectively a reverse mergertipranks.com. Under the proposal, Flash will be absorbed into new Urban-gro subsidiaries, and Flash’s shareholders will receive new Urban-gro shares (unregistered) equal to 19.99% of UGRO’s pre-merger common stock, plus a new series of preferred shares that convert to common upon shareholder approvalsec.govsec.gov. Once the dust settles, Flash’s owners would
14 October 2025
·····
Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Latest News & Developments On Oct. 14, 2025, Astria was swept into the headlines by a surprise $700+ million takeover. BioCryst Pharmaceuticals announced a definitive merger agreement to acquire Astria for $8.55 in cash plus 0.59 shares of BioCryst stock per Astria share (≈$13.00 total) marketscreener.com reuters.com. This values Astria at roughly $920M equity and $700M enterprise stocktitan.net. The Boards of both companies approved the deal, which is expected to close in Q1 2026 (subject to approvals) stocktitan.net. Astria CEO Jill Milne will join BioCryst’s board post-merger stocktitan.net. Market reaction: News of the deal caused Astria’s stock to jump sharply.
14 October 2025
····
BlackRock’s GIP Poised for $38B AES Power Grab – AI-Fuelled Demand Sparks Takeover Frenzy

BlackRock Soars: Crypto ETFs, AI Funds and Mega M&A Propel Assets to Record $13.5T

BlackRock’s latest earnings and moves underscore its market heft and broad strategy. CEO Larry Fink observed that “record demand” across the firm’s businesses — from technology-driven funds to private credit and ETFs — powered the quarterreuters.com. In particular, strong flows into lower-cost index and cash products (helped by the Fed’s recent rate cut) drove the fee bump. An analyst noted that all of BlackRock’s new private-market businesses (HPS, Preqin, GIP) “made healthy contributions” to Q3 resultsreuters.com, validating BlackRock’s aggressive M&A in 2025. Larry Fink said the unified public-private platform positions BlackRock well for what he expects will be a strong
14 October 2025
···
EasyJet Stock Skyrockets on Takeover Rumours – MSC Denies Interest

EasyJet Stock Skyrockets on Takeover Rumours – MSC Denies Interest

What’s Happening? On Oct 14 an Italian newspaper (Corriere della Sera) reported that MSC, the world’s largest container-ship operator, is exploring a bid for EasyJet. The report said MSC might team up with an investment fund to buy a stake or even full control of the UK airlineproactiveinvestors.commarketscreener.com. In early London trading EasyJet stock soared (hitting 11.5% gains) on the newsreuters.com. By late morning the jump had eased to mid-single digits, especially after MSC publicly denied the rumours. MSC’s emailed statement – “MSC denies any involvement in this matter” – was picked up by Reuters and dampened some of the
14 October 2025
····
PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

Company Overview PMGC Holdings Inc. (NASDAQ: ELAB) is a diversified holding company that grows by acquisitions. Its profile describes it as managing a portfolio of subsidiaries through strategic deals Reuters. Notably, one subsidiary – NorthStrive Biosciences – is a biopharma/medtech firm developing aesthetic and obesity-related treatments (e.g. an engineered probiotic “EL-22” for muscle retention) Reuters. The other arms (PMGC Research, PMGC Capital) provide R&D and investment vehicles. However, PMGC’s recent focus is industrial: it seeks cash-flow positive U.S.-based manufacturing businesses (CNC machining, packaging, etc.) to bolt onto its platform Sec Tipranks. In Jan 2025 the company sold its former skincare
14 October 2025
·····
Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Overview of Strive and Its Role: Strive Asset Management began as an ETF issuer and anti-ESG investment firm (co-founded by Ramaswamy in 2022)etf.comglobenewswire.com. In 2025 it transformed into a dedicated Bitcoin-treasury company. Strive’s business is to raise capital (through equity/debt) and convert it into Bitcoin holdings. The company uses a “preferred equity only” leverage model (no debt) to accumulate cryptoglobenewswire.com. By merger and acquisitions, Strive aims to become a large public company that simply hoards Bitcoin. Its own COO calls this building a “scaled, innovative and accretive Bitcoin acquisition platform”globenewswire.com. In practice, Strive is effectively a corporatized Bitcoin ETF: shareholders
11 October 2025
····
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseasesprotagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platformprotagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate. Leadership & Culture: President
11 October 2025
·······
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonistreuters.com. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that J&J is negotiating a purchase of Protagonist Therapeuticsreuters.com. This potential acquisition would build on the companies’ ongoing partnership: J&J’s Janssen unit has held exclusive worldwide rights to develop and commercialize Protagonist’s peptide drug Icotrokinra (JNJ-2113) since a 2017 collaboration dealreuters.com. In fact, J&J already holds rights to market Icotrokinra and reportedly owns a ~4% stake in Protagonist, reflecting its early confidence in the
10 October 2025
·····
1 … 29 30 31 32 33 34

Stock Market Today

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

7 February 2026
LONDON, February 7, 2026, 08:48 GMT — Market closed Lloyds Banking Group shares finished Friday higher after the lender flagged another round of share buybacks, helping to steady the stock at the end of a volatile two-day swing driven by shifting expectations for UK interest rates. With London markets closed for the weekend, the focus moves to Monday’s open and whether rate-cut pricing keeps easing pressure on bank earnings. Lloyds is a UK-focused lender, and investors tend to treat it as a clean play on domestic growth, mortgages and the direction of Bank Rate. That makes the stock quick to
Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
Go toTop